Revenue from Vaxini was pressured by lower average selling prices linked to higher rebates and 340B discounts; these pricing headwinds are expected to persist in the near term according to management ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, prompting a negative market reaction. Management ...

Image source: The Motley Fool. Amphastar Pharmaceuticals (NASDAQ:AMPH) delivered quarterly revenue growth from new launches and stable core products while facing substantial pricing and competitive ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical ...

Changes in net revenues as compared to the first quarter of the prior year were primarily driven by: BAQSIMI ® sales decreased primarily due to a lower average selling price, as a result of a change ...

Dan Dischner (Senior Vice President of Human Resources & Corporate Communication) said Q1 reflected “a return to growth, driven primarily by contributions from recent product launches,” while the ...

Greetings, and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not ...

Amphastar Pharmaceuticals (NASDAQ:AMPH) presented its corporate overview in May 2026, showcasing an ambitious strategic transformation toward proprietary and biosimilar products even as the company ...

Experts are urging anyone who is using a blue salbutamol inhaler to contact their GP. The familiar blue reliever treatment has been used by millions of asthma patients for over five decades. However ...